Ji-Sun Kim

Ji-Sun Kim

Auto-generated profile, based on publicly available information

Ji-Sun Kim

Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2023 in Nature Computational Science
Verified
Journal Article
Closed access
PDF file
JLJin Sub Lee
Jin Sub Lee
JKJisun Kim
Jisun Kim
PKPhilip M. Kim
Philip M. Kim

17 January 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
SSSeung-Min Shin
Seung-Min Shin
JKJi-Sun Kim
Ji-Sun Kim
SPSeong-Wook Park
Seong-Wook Park
JSJun Sei-Yong
Jun Sei-Yong
HKHye-Jin Kweon
Hye-Jin Kweon
Yong-Sung KimYong-Sung Kim
Yong-Sung Kim
Oncogenic RAS mutant (RASMUT) proteins have been considered undruggable via conventional antibody regimens owing to the intracellular location restricting conventional-antibody accessibility. Here, we report a pan-RAS–targeting IgG antibody, inRas37, which directly targets the intracellularly activated form of various RASMUT subtypes after tumor cell–specific internalization into the cytosol to block the interactions with effector proteins, thereby suppressing the downstream signaling. Systemic administration of inRas37 exerted a potent antitumor activity in a subset of RASMUT tumor xenografts in mice, but little efficacy in RASMUT tumors with concurrent downstream PI3K mutations, which were overcome by combination with a PI3K inhibitor. The YAP1 protein was up-regulated as an adaptive resistance-inducing response to inRas37 in RASMUT-dependent colorectal tumors; accordingly, a combination of inRas37 with a YAP1 inhibitor manifested synergistic antitumor effects in vitro and in vivo. Our study offers a promising pan-RAS–targeting antibody and the corresponding therapeutic strategy against RASMUT tumors.

19 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SNSatra Nim
Satra Nim
DODarren M. O’hAra
Darren M. O’hAra
CCCarles Corbi-Verge
Carles Corbi-Verge
APAlbert Perez-Riba
Albert Perez-Riba
KFKazuko Fujisawa
Kazuko Fujisawa
PKPhilip M. Kim
Philip M. Kim
Accumulation of α-synuclein into toxic oligomers or fibrils is implicated in dopaminergic neurodegeneration in Parkinson’s disease. Here we performed a high-throughput, proteome-wide peptide screen to identify protein-protein interaction inhibitors that reduce α-synuclein oligomer levels and their associated cytotoxicity. We find that the most potent peptide inhibitor disrupts the direct interaction between the C-terminal region of α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B), a component of the Endosomal Sorting Complex Required for Transport-III (ESCRT-III). We show that α-synuclein impedes endolysosomal activity via this interaction, thereby inhibiting its own degradation. Conversely, the peptide inhibitor restores endolysosomal function and thereby decreases α-synuclein levels in multiple models, including female and male human cells harboring disease-causing α-synuclein mutations. Furthermore, the peptide inhibitor protects dopaminergic neurons from α-synuclein-mediated degeneration in hermaphroditic C. elegans and preclinical Parkinson’s disease models using female rats. Thus, the α-synuclein-CHMP2B interaction is a potential therapeutic target for neurodegenerative disorders.

1 September 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JKJi-Sun Kim
Ji-Sun Kim
JPJae-Yeong Park
Jae-Yeong Park
SSSeung-Min Shin
Seung-Min Shin
SPSeong-Wook Park
Seong-Wook Park
SJSei-Yong Jun
Sei-Yong Jun
Yong-Sung KimYong-Sung Kim
Yong-Sung Kim

7 September 2025 in bioRxiv
Verified
Preprint
Open access
KJKyeong Beom Jo
Kyeong Beom Jo
MAMohammed M. Alruwaili
Mohammed M. Alruwaili
DKDa-Eun Kim
Da-Eun Kim
YKYongjun Koh
Yongjun Koh
KYKwontae You
Kwontae You
DKDae-Kyum Kim
Dae-Kyum Kim
Background : Conventional chemotherapies remain the core therapeutic backbone of cancer treatment, yet the rapid emergence of chemoresistance often compromises their clinical efficacy. Although large-scale functional genomics has transformed precision oncology, existing reference maps rely predominantly on loss-of-function paradigms and lack systematic data on gain-of-function (GOF) events that commonly drive clinical resistance. Methods : To address this gap, we engineered a site-specific Bxb1 integrase landing-pad system in HeLa cells, enabling single-copy integration of a human proteome-wide library [18,388 open reading frames (ORFs)] at the AAVS1 locus under a uniform EF1α promoter. We systematically profiled cellular fitness across 16 chemotherapeutics. We integrated this GOF perturbation screen with bulk and single-cell RNA sequencing, FACS-based lysosomal functional screening, clinical cohort survival analyses, and preclinical xenograft modeling. Results : Stratified modeling of over 230,000 gene-drug interactions defined distinct functional categories that are strongly enriched for clinical cancer biomarkers and prognostic relevance. Global network analysis and organelle-specific lysosomal functional screening uncovered that chemotherapeutic agents, most prominently the nucleoside analog TAS-102 (Lonsurf), converge upon a shared survival hub centered on the BCL-2 family-associated autophagy-endolysosomal network. Mechanistically, TAS-102 triggered lysosomal activation as an adaptive survival response. Co-treatment with the BCL-2 family inhibitor ABT-263 (Navitoclax) attenuated this TAS-102-induced lysosomal response and synergistically reversed TAS-102 resistance across colorectal and pancreatic cancer models in vitro and in colorectal cell line- and patient-derived xenograft (CDX, PDX) models in vivo. Conclusions : Our study establishes an open-access, proteome-wide GOF reference atlas that systematically maps chemotherapeutic responses, recapitulates canonical resistance biology, and nominates rational drug combinations. This systems-genomics resource bridges massive-scale perturbation mapping with actionable target discovery, providing a translational framework to overcome therapeutic resistance and reprogram cancer drug responses.

1 May 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
SSSeung-Min Shin
Seung-Min Shin
JKJi-Sun Kim
Ji-Sun Kim
JHJin-Sun Hong
Jin-Sun Hong
SPSeong-Wook Park
Seong-Wook Park
JSJun Sei-Yong
Jun Sei-Yong
Yong-Sung KimYong-Sung Kim
Yong-Sung Kim
Oncogenic Ras mutants, and most frequently KRas mutants (86% of Ras-driven cancers), are found in approximately 25% of human cancers and are high-priority anticancer drug targets. Despite 30 years of effort to develop drugs that directly target oncogenic Ras mutants, no effective pharmacologic inhibitors for these mutants are clinically available, mainly because of the lack of suitable surface binding pockets for small molecules. More than 50 therapeutic antibodies have been clinically approved against many extracellular proteins. However, such antibodies do not have the capacity to localize in intracellular cytosolic regions after receptor-mediated endocytosis, restricting their therapeutic application for targeting cytosolic proteins. Our group recently developed a platform technology of cytosol-penetrating antibody, which in the IgG format can reach the cytosolic space of living cells owing to its endosomal escaping ability after receptor-mediated endocytosis. Exploiting the cytosol-penetrating antibody technology, we have engineered a human IgG1 format antibody, named iMab (internalizing and protein-protein interaction [PPI] interfering monoclonal antibody), which internalizes into the cytosol of living cells and selectively binds to the activated GTP-bound form of oncogenic Ras mutants. iMab specifically binds to the PPI interfaces of activated Ras with effector proteins to block the associations, thereby inhibiting the Ras downstream oncogenic signaling and exerting antiproliferation effects on oncogenic Ras mutant tumor cells. For in vivo antitumor efficacy assessment, we further engineer iMab to have tumor tissue-homing ability by fusion of tumor-associated integrin αvβ3/αvβ5 binding cyclic peptide to the N-terminus of light chain. When systemically administered, the iMab variant significantly inhibited the in vivo growth of oncogenic Ras-mutated tumor xenografts in mice, but not wild-type Ras-harboring tumors. Our results demonstrate the feasibility of developing antibody therapeutics that directly target cytosolic proteins involved in disease-associated PPIs, such as oncogenic Ras mutants, by systemic administration, similar to conventional therapeutic antibody regimens. Because the oncogenic Ras targeting antibody holds many desirable features of the conventional IgG antibody, it shows great potential for development as a first-in-class anticancer antibody. Citation Format: Seung-Min Shin, Ji-Sun Kim, Jin-Sun Hong, Seong-wook Park, Sei-Yong Jun, Hye-Jin Kweon, Dong-Ki Choi, Yong-Sung Kim. Direct targeting oncogenic Ras mutants by IgG-format cytosol-penetrating antibody [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr B28.